Outset Medical 10-Q: Q3 Revenue $33.6M, Loss Narrows, New FDA Form 483 Disclosed
OM sits 56% above its 52-week low of $2.841.
Summary
Outset's Q3 10-Q confirms $33.6M revenue (up 14%), a $14.7M net loss and $140.7M of liquidity, while disclosing a new FDA Form 483 from a Q3 inspection and a warrant strike cut to $4.838.
Key Events · Earnings and Guidance · OM
-
Q3 Revenue Up 14% to $33.6M
Total revenue rose to $33.6 million from $29.4 million, driven by a $3.1 million (15%) increase in product revenue; nine-month revenue was $93.1 million versus $90.6 million.
-
Loss Narrows, Gross Margin Improves
Net loss was $14.7 million ($0.78 per share) versus $17.8 million ($1.00) a year ago; gross margin improved 1.3 points to 40.7% and 3.8 points to 41.7% for the nine months.
-
New FDA Form 483 at San Jose
A Q3 2026 post-market quality system inspection produced a Form 483 citing observations on CAPAs, complaint handling and reporting, change documentation and data analysis; the company has responded and warns costs may be significant.
-
$140.7M Liquidity, 12-Month Runway
Cash, equivalents, restricted cash and short-term investments totaled $140.7 million at September 30, 2026, against $32.9 million of nine-month operating cash burn; management sees at least 12 months of funding.
Analysis · OM · Industrial Applications And Services
The headline numbers were already out via this morning's press release, but the 10-Q carries two things the release did not: a fresh FDA Form 483 from a Q3 post-market inspection of the San Jose plant (CAPA, complaint handling, change documentation, data analysis), and confirmation that the Perceptive warrant strike was reset to $4.838 from $12.00. Against a $140.7M liquidity cushion and $32.9M of nine-month operating burn, the company says it has at least 12 months of runway — but a Form 483 that escalates to a warning letter would put the whole thesis at risk, and the warrant reset means 375,000 shares now sit close to in-the-money.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OM was trading at $4.43 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $83.4M. The 52-week trading range was $2.84 to $12.97. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.